AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11491415 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 82
Study 9760011 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg desmopressin (dDAVP)
Number of subjects: 16
Study 9760011 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 16
Study 9316691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (120 mg/day)
Number of subjects: 2
Study 9316691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3219881 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 24
Study 3219881 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 24
Study 29607323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity cycling (LC)
Number of subjects: 36
Study 29607323 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling (MC)
Number of subjects: 36
Study 29607323 — intervention group
Group type: COMPARATOR
Intervention: Standing
Number of subjects: 36
Study 27629371 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical management (MISM)
Number of subjects: 101
Study 27629371 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 101
Study 25536706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized powder of EPO alpha
Number of subjects: 40
Study 25536706 — intervention group
Group type: COMPARATOR
Intervention: Liquid form of EPO alpha
Number of subjects: 40
Study 22732136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with silicone tubing (stent)
Number of subjects: 173
Study 22732136 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic DCR without silicone tubing (no stent)
Number of subjects: 173
Study 22732136 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 173
Study 22732136 — intervention group
Group type: COMPARATOR
Intervention: Comparison of failure rates
Number of subjects: 173
Study 20022777 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta in Cohort 1B
Number of subjects: 244
Study 20022777 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) prior to October 2006 in Cohort 1A
Number of subjects: 244
Study 20022777 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history of disease complications in Cohort 1C (no ERT)
Number of subjects: 244
Study 18710324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV) followed by protein‐conjugate pneumococcal vaccine (PCV)
Number of subjects: 0
Study 18710324 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐conjugate pneumococcal vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0
Study 18710324 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0
Study 18710324 — intervention group
Group type: COMPARATOR
Intervention: Protein‐conjugate pneumococcal vaccine (PCV)
Number of subjects: 0
Study 18710324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV) as a booster after PCV
Number of subjects: 0
Study 15695301 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (thalassotherapy, supervised exercise, and group education)
Number of subjects: 58
Study 15695301 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (treatment as usual)
Number of subjects: 58
Study 12112158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 50
Study 12112158 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication alone (Control)
Number of subjects: 50
Study 10430767 — intervention group
Group type: EXPERIMENTAL
Intervention: Total circulatory arrest (CA)
Number of subjects: 158
Study 10430767 — intervention group
Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 158
Study 10430767 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures in the perioperative period
Number of subjects: 158
Study 7555553 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula without intact cow's-milk protein
Number of subjects: 83
Study 7555553 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study 2210464 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily for 12 weeks
Number of subjects: 43
Study 2210464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily for 12 weeks plus cefixime 100 mg daily for the last two weeks
Number of subjects: 43
Study 2210464 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine only (H pylori positive)
Number of subjects: 43
Study 2210464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus cefixime (H pylori suppressed)
Number of subjects: 43
Study 2210464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (at 24 weeks)
Number of subjects: 43
Study 476225 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO scale for women in group A
Number of subjects: 66
Study 476225 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO scale for men in group A
Number of subjects: 66
Study 476225 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO scales applied to another population
Number of subjects: 66
Study 31296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 1 mg daily
Number of subjects: 40
Study 31296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 2 mg daily
Number of subjects: 40
Study 31296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 4 mg daily
Number of subjects: 40
Study 31296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 8 mg daily
Number of subjects: 40
Study 31296884 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study 28187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq®
Number of subjects: 20
Study 28187213 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath®
Number of subjects: 20
Study 28187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh
Number of subjects: 20
Study 28187213 — intervention group
Group type: COMPARATOR
Intervention: Airtraq® vs McGrath®
Number of subjects: 20
Study 28187213 — intervention group
Group type: COMPARATOR
Intervention: Airtraq® vs Macintosh
Number of subjects: 20
Study 28187213 — intervention group
Group type: COMPARATOR
Intervention: All devices
Number of subjects: 20
Study 25862600 — intervention group
Group type: EXPERIMENTAL
Intervention: sotDCS (0.75 Hz; 0-250 μV, 30 min)
Number of subjects: 12
Study 25862600 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 12
Study 24112746 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (initial dose 20μg/hour, increased by 20μg/hour every 6 hours up to 80μg/hour for a maximum of 48 doses)
Number of subjects: 200
Study 24112746 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol tablets (25μg every 6 hours for a maximum of 8 doses)
Number of subjects: 200
Study 24112746 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 200
Study 21900191 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (30 U/kg body weight/infusion)
Number of subjects: 29
Study 21900191 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (60 U/kg body weight/infusion)
Number of subjects: 29
Study 19638025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task conditions (oral counting task)
Number of subjects: 39
Study 19638025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task conditions (auditory-verbal reaction task)
Number of subjects: 39
Study 19638025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task conditions (auditory-memory task)
Number of subjects: 39
Study 19638025 — intervention group
Group type: COMPARATOR
Intervention: Dual-task conditions (auditory-choice reaction task)
Number of subjects: 39
Study 19638025 — intervention group
Group type: COMPARATOR
Intervention: Dual-task conditions (articulation alone)
Number of subjects: 39
Study 17717929 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xiaoyao Pill combining amitriptyline (MXP-At)
Number of subjects: 64
Study 17717929 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (control group)
Number of subjects: 64
Study 15190050 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng
Number of subjects: 12
Study 15190050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnamese ginseng
Number of subjects: 12
Study 15190050 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian ginseng
Number of subjects: 12
Study 15190050 — intervention group
Group type: EXPERIMENTAL
Intervention: American-wild ginseng
Number of subjects: 12
Study 15190050 — intervention group
Group type: EXPERIMENTAL
Intervention: Siberian ginseng
Number of subjects: 12
Study 15190050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11587992 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (3 months)
Number of subjects: 400
Study 11587992 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms for PE
Number of subjects: 400
Study 11587992 — intervention group
Group type: COMPARATOR
Intervention: Nondiagnostic lung scan
Number of subjects: 400
Study 9519224 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 4 mg nebulized suspension
Number of subjects: 26
Study 9519224 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1 mg nebulized suspension
Number of subjects: 26
Study 9519224 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 0.8 mg pMDI with spacer
Number of subjects: 26
Study 9519224 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma budesonide levels
Number of subjects: 26
Study 9519224 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 26
Study 7865997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Migu Ye (BSMGY)
Number of subjects: 43
Study 7865997 — intervention group
Group type: COMPARATOR
Intervention: Control group (Rhizoma Dioscoreae decoction)
Number of subjects: 43
Study 2511532 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot gonadotropin-releasing hormone analogue (leuprolide) given monthly for 24 weeks
Number of subjects: 11
Study 2511532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 887103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral choline administration for two weeks
Number of subjects: 20
Study 30093401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (2.5-10 mg/m2) administered in 1-4 cycles as a single agent (47%), combined with cytarabine (47%), or others (6%)
Number of subjects: 76
Study 30093401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 76
Study 28476923 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (70ml, 6.4 mmol nitrate)
Number of subjects: 14
Study 28476923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) (0.0055 mmol nitrate)
Number of subjects: 14
Study 25796535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board anteroposterior sway velocity
Number of subjects: 73
Study 25796535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board mediolateral sway velocity
Number of subjects: 73
Study 25796535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board anteroposterior sway velocity adjusted with body mass index and Timed-Up-and-Go
Number of subjects: 73
Study 25796535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board sway velocities
Number of subjects: 73
Study 24374539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any complication (215 patients)
Number of subjects: 614
Study 24374539 — intervention group
Group type: COMPARATOR
Intervention: Patients without complications (399 patients)
Number of subjects: 614
Study 24374539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any of 5 common complications (wound, chest, anastomotic leak, hemorrhage, cardiac event)
Number of subjects: 614
Study 24374539 — intervention group
Group type: COMPARATOR
Intervention: Patients without any of the 5 common complications
Number of subjects: 614
Study 21901499 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus website (E-info gene(ca))
Number of subjects: 190
Study 21901499 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 190
Study 19737502 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld Assisted Network Diary (HAND) assessment
Number of subjects: 168
Study 19737502 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil Daily Social Diary (DSD)
Number of subjects: 168
Study 17714104 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 milliTESLA (mT) treatment using a prototype electromagnetic field device
Number of subjects: 40
Study 17714104 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 15113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding to 6 months (EBF)
Number of subjects: 119
Study 15113951 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified complementary foods (SF) from 4 to 6 months while continuing to breast-feed
Number of subjects: 119
Study 15113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal iron supplements
Number of subjects: 119
Study 11677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol treatment
Number of subjects: 231
Study 11677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 231
Study 9439541 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infusion (25 ng/kg/min)
Number of subjects: 8
Study 7886779 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine, 14 mg/kg/d (max. 1 g daily) for 20 days
Number of subjects: 34
Study 7886779 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate, 20 mg/kg/d for 20 days
Number of subjects: 34
Study 2979254 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 8.75, 17.5, 35 and 70 micrograms
Number of subjects: 9
Study 2979254 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 9
Study 30486262 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise (n = 18)
Number of subjects: 54
Study 30486262 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home‐based exercise (n = 18)
Number of subjects: 54
Study 30486262 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 54
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: No CAD (SS=0)
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: Low SS (SS between 1 and 22)
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: Intermediate SS (SS between 23 and 32)
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: High SS (SS ≥33)
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: Residual SS ≥8
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: Low CABG SS
Number of subjects: 377
Study 28219920 — intervention group
Group type: COMPARATOR
Intervention: High CABG SS
Number of subjects: 377
Study 26163093 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted palliative radiotherapy (RT) course: 39Gy in 13 fractions (arm A)
Number of subjects: 65
Study 26163093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CHT) followed by short-course palliative RT: 2-3 platinum-based CHT cycles followed by 10Gy in a single fraction or 16Gy in 2 fractions (arm B)
Number of subjects: 65
Study 26163093 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 65
Study 23066808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT), a nonverbal, computerized intervention involving perceptual practice of visual tasks
Number of subjects: 126
Study 23066808 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 126
Study 21290963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month self-efficacy-based, individually delivered, lower-extremity exercise and fitness walking intervention
Number of subjects: 26
Study 19193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 4890
Study 19193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 4890
Study 19193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent episode patients
Number of subjects: 4890
Study 19193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single episode patients
Number of subjects: 4890
Study 16608044 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch interposition (JPI)
Number of subjects: 9
Study 16608044 — intervention group
Group type: COMPARATOR
Intervention: Jejunal interposition (JI)
Number of subjects: 9
Study 14735685 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study 14735685 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 0
Study 15126606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile)
Number of subjects: 1163
Study 15126606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among men diagnosed after 1990
Number of subjects: 1163
Study 15126606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among case subjects with elevated baseline PSA levels (PSA >4 ng/mL)
Number of subjects: 1163
Study 10491060 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-15 mmHg gradient compression hosiery
Number of subjects: 19
Study 10491060 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-20 mmHg gradient compression hosiery
Number of subjects: 19
Study 10491060 — intervention group
Group type: COMPARATOR
Intervention: No compression
Number of subjects: 19
Study 7572650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 28
Study 7572650 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg 4 times daily
Number of subjects: 28
Study 1690482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial)
Number of subjects: 58
Study 1690482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 376211 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50 mg) 3 times a day
Number of subjects: 6
Study 376211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg) 3 times a day
Number of subjects: 6
Study 376211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31287130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baska mask
Number of subjects: 150
Study 31287130 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 150
Study 31287130 — intervention group
Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 150
Study 26910406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 284
Study 26910406 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 284
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI = 100% (complete revascularization)
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI between 50% to <100%
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI <50%
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI cutoff <70%
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean bSS
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ΔSS after PCI
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean residual SYNTAX score
Number of subjects: 888
Study 25983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SRI
Number of subjects: 888
Study 24302192 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and inositol
Number of subjects: 149
Study 24302192 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 149
Study 21229373 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 240
Study 21229373 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide
Number of subjects: 240
Study 21229373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 240
Study 19528337 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 263
Study 19528337 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 263
Study 17169471 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-month-olds processing of happy faces
Number of subjects: 2
Study 17169471 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month-olds processing of angry faces
Number of subjects: 2
Study 17169471 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual preference assessment in infants
Number of subjects: 2
Study 15521372 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 33
Study 15521372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 33
Study 15521372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11709743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisequens(R) for 28 days
Number of subjects: 50
Study 11709743 — intervention group
Group type: COMPARATOR
Intervention: Sisare(R) for 21 days
Number of subjects: 50
Study 11709743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisequens(R)
Number of subjects: 50
Study 11709743 — intervention group
Group type: COMPARATOR
Intervention: Sisare(R)
Number of subjects: 50